Pivotal Software

Pivotal is a software company that provides digital transformation technology and services. Its Cloud Native platform drives software innovation for many of the world’s most admired brands. With millions of developers in communities around the world, Pivotal technology touches billions of users every day. After shaping the software development culture of Silicon Valley's most valuable companies for over a decade, today Pivotal leads a global technology movement transforming how the world builds software.

KIRKLAND, Wash.--(BUSINESS WIRE)--Appen Limited (Appen) (ASX: APX) the leading training data for AI company that makes trusted deep learning and generative AI work better for everyone, today announced the appointment of Andrew Ettinger as Chief Revenue Officer (CRO), effective 22 May 2023. For more than 25 years Appen has successfully helped some of the largest big tech and enterprise customers adapt deep learning AI and generative AI solutions. Andrew will direct Appen's global go-to-market sa.

Appen appoints former Pivotal Software and Astronomer SaaS executive Andrew Ettinger to lead worldwide sales

Appen Appoints Former Pivotal Software and Astronomer SaaS Executive Andrew Ettinger to Lead Worldwide Sales

VMware

VMware (VMW) completes the acquisition of Pivotal Software in a bid to expand its enterprise-grade Kubernetes-based offerings for modern applications.

VMware (VMW) Completes the Acquisition of Pivotal Software

VMware is closing the year with a significant new component in its arsenal. Today it announced it has closed the $2.7 billion Pivotal acquisition it originally announced in August.

VMware completes $2.7 billion Pivotal acquisition

Pivotal Software (PVTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pivotal Software (PVTL) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Adobe

Dell Technologies

Microsoft

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Cloud computing is growing rapidly and with an estimated CAGR of 22.3% in 2023 investing in these five stocks might be beneficial for investors.

5 Stocks to Make the Most of the Cloud Computing Boom

NEWTOWN, Pa., Oct.  24, 2019  (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a focus on myelodysplastic syndromes (MDS), announced that the Company believes it remains on target to report top-line data from the global Phase 3 INSPIRE Trial with intravenous (IV) rigosertib in second-line, higher-risk MDS patients in the first half of 2020 following full enrollment and 288 death events.  The Company anticipates completion of the INSPIRE Trial in the first half of 2020 based on approaching 90 percent or 324 randomized patients of the required 360 randomized patients, and the number of confirmed death events reached to date. 

Onconova Affirms Planned Completion of Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes by 1H20 And Provides Research & Development Update

Alibaba

The Linux Foundation recently announced the launch of the Reactive Foundation. Its founding members are Alibaba, Lightbend, Pivotal and Netifi.

With Alibaba, Pivotal and Lightbend on board, Reactive flexes its ROI muscle in the microservices world

Medtronic

Study to Evaluate Novel Implantable Defibrillator System with a Lead Placed Outside the Heart and Veins Study to Evaluate Novel Implantable Defibrillator System with a Lead Placed Outside the Heart and Veins

Medtronic Initiates Worldwide Pivotal Study of a New Approach to Treating Dangerously Fast Heart Rhythms

Tyme (TYME) initiates the pivotal stage of the TYME-88-Panc study evaluating oral SM-88 (racemetyrosine) for third-line treatment of patients with metastatic pancreatic cancer.

Tyme Initiates Pivotal Stage of Pancreatic Cancer Study

NEW YORK and CLEVELAND, Sept.  23, 2019  (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it has recently received a clinical hold letter from the U.S. Food and Drug Administration (FDA) clarifying that the FDA will not provide approval for the Company to begin its planned Phase 3 clinical trial for EB-101 until it submits to the FDA additional data points on transport stability of EB-101 to clinical sites. Over the last 12 months, the Company has worked closely with the FDA to address and narrow open Chemical, Manufacturing and Controls (CMC) items and has been working to resolve this one item identified in the FDA Clinical Hold Letter. The Company continues to anticipate receiving CMC clearance for VIITAL™ trial in Q4 2019.

Abeona Therapeutics Provides Regulatory Update Ahead of Pivotal Phase 3 Clinical Trial for EB-101 in Recessive Dystrophic Epidermolysis Bullosa

DUBLIN, Ireland, Sept.  23, 2019  (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing once-nightly sodium oxybate, FT218, for narcolepsy, today announced that the U.S. Food and Drug Administration (FDA) has agreed to the Company’s proposed amendments to the statistical analysis plan and protocol under its special protocol assessment agreement (SPA), resulting in a lower sample size needed to demonstrate significance for both excessive daytime sleepiness and cataplexy in narcolepsy patients.  No modifications were made to the fundamental design of the study, including the primary or secondary endpoints, dosing scheme or duration of the study, and the SPA remains intact.

Avadel Pharmaceuticals Announces FDA Agreement to Reduce the Sample Size for the Ongoing Pivotal Phase 3 Study for Once-Nightly FT218; Full Enrollment Now Expected by End of 2019

The cloud-native platform specialist is being acquired. Here's what investors need to know.

Why Pivotal Software Stock Soared 57.3% in August

Pivotal Software (PVTL) delivered earnings and revenue surprises of 100.00% and 3.58%, respectively, for the quarter ended July 2019. Do the numbers hold clues to what lies ahead for the stock?

Pivotal Software (PVTL) Reports Break-Even Earnings for Q2

On Wednesday, September 4, Pivotal Software (NYSE: PVTL) will release its latest earnings report.

A Preview Of Pivotal Software's Q2 Earnings

uniQure

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Sept.  03, 2019  (GLOBE NEWSWIRE) --  uniQure N.V.  (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced that the planned enrollment of 56 patients has been achieved in the HOPE-B pivotal trial of  etranacogene dezaparvovec (AMT-061  ), an investigational  AAV5 -based gene therapy incorporating the patent-protected FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B. Due to the high level of interest in the study from both patients and study investigators, uniQure expects to over-enroll up to six additional patients before the end of September.  Etranacogene dezaparvovec has been granted Breakthrough Therapy Designation by the United States Food and Drug Administration and access to Priority Medicines (PRIME) regulatory initiative by the European Medicines Agency.

uniQure Announces Achievement of Planned Enrollment in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Patients with Hemophilia B

Will Pivotal Software (PVTL) Report Negative Earnings Next Week? What You Should Know

Virtualization technology pioneer VMware, Inc. (NYSE: VMW) said last week it had inked a definitive deal to acquire Pivotal Software Inc (NYSE: PVTL) for $15 per share.

KeyBanc Downgrades Pivotal Software After VMware Acquisition Bid

Pivotal Software (PVTL) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Pivotal Software (PVTL) Catches Eye: Stock Jumps 8.6%

Carbon Black Inc

Red Robin

Bad news from China took a bite out of the stock market.

Why Pivotal Software, Carbon Black, and Red Robin Gourmet Burgers Jumped Today

The software company announced two big acquisitions along with its second-quarter report.

VMware Goes Shopping for Cloud Growth

Pivotal Software (PVTL) stock is heading higher on Friday thanks to a deal with VMware (VMW) that values the company at $2.70 billion.
The post Pivotal Software (PVTL) Stock Rockets Higher on VMware Deal appeared first on InvestorPlace.

Pivotal Software (PVTL) Stock Rockets Higher on VMware Deal

VMware Inc. has been snapping up cloud-focused startups while making deals with former enemies like Amazon.com Inc.

VMware transformation speeds up with deals for Pivotal Software, Carbon Black

VMware today announced that it is acquiring Carbon Black, a publicly traded security company that focuses on securing modern cloud-native workloads. The price of the acquisition is about $2.1 billion.

VMware acquires Carbon Black for $2.1B and Pivotal for $2.7 billion

VMware, Inc. (NYSE: VMW) announced two different acquisition after Thursday's market close.

News for Pivotal Software Stock (PVTL)